N@N

NICE, ALTI, THLD, MT, PESI, XOMA Expected To Be Down After Next Earnings Releases

November 2, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, November 3rd 2011 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. NICE SYSTEMS LTD-SPONS ADR (NASDAQ:NICE), ALTAIR NANOTECHNOLOGIES INC (NASDAQ:ALTI), THRESHOLD PHARMACEUTICALS (NASDAQ:THLD), ARCELORMITTAL-NY REGISTERED (NYSE:MT), PERMA-FIX ENVIRONMENTAL SVCS (NASDAQ:PESI), XOMA LTD (NASDAQ:XOMA) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Thursday:

     Symbol     Company                             # of Reports            Quarter     Release Time
     NICE       NICE SYSTEMS LTD-SPONS ADR          12 Quarter              Q3          Before
     ALTI       ALTAIR NANOTECHNOLOGIES INC         12 Quarter              Q3          Before
     THLD       THRESHOLD PHARMACEUTICALS           12 Quarter              Q3          After
     MT         ARCELORMITTAL-NY REGISTERED         6 Quarter               Q3          Before
     PESI       PERMA-FIX ENVIRONMENTAL SVCS        12 Quarter              Q3          Before
     XOMA       XOMA LTD                            November Earnings       Q3          After

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

NICE SYSTEMS LTD-SPONS ADR (NASDAQ:NICE) - NICE Systems Ltd., together with its subsidiaries, provides solutions that enable enterprises and security organizations to extract insight from interactions, transactions, and surveillance. It offers a suite of business solutions to capture, analyze, and impact customer interactions over various channels, including audio, email, chat, social media, and text messaging. The company also provides securities trading and broker sales practices compliance applications to identify high-risk activities by monitoring and correlating various data elements comprising transactions, accounts, trader information, interactions, and market activities; fraud prevention solutions for the identification of financial crimes, such as employee fraud or rogue trading, online and call center fraud, payment fraud, and ATM fraud; AML solutions to detect suspicious money transfer activities and money laundering related issues with new accounts; and enterprise wide case management and investigation applications that are used to aggregate, analyze, and investigate risk related cases in the organization. Further, it offers various security solutions, such as voice platforms and applications; digital video platforms and applications; and lawful interception products, as well as provides professional, consultancy, and legacy services. The company serves various industries, such as financial services, telecommunications, healthcare, outsourcers, retail, media, travel, service providers, and utilities. NICE Systems offers its products through a network of distributors, system integrators, and strategic partners, as well as directly to end-users in North America, Europe, the Middle East and Africa, and the Asia Pacific. The company was formerly known as NICE Neptun Intelligent Computer Engineering Ltd. and changed its name to NICE Systems Ltd. in October 1991. NICE Systems Ltd. was founded in 1986 and is based in Ra'anana, Israel.

ALTAIR NANOTECHNOLOGIES INC (NASDAQ:ALTI) - Altair Nanotechnologies, Inc. develops, manufactures, and sells rechargeable lithium ion batteries in the United States and internationally. It offers nano lithium titanate battery cells, batteries, and battery packs, as well as provides related design, installation, and test services. The company also provides contract research services to develop intellectual property and/or new products and technology. It markets its energy storage solutions to power companies and electric grid operators, as well as battery products to the electric and hybrid-electric mass-transit markets. The company was formerly known as Altair International Inc. and changed its name to Altair Nanotechnologies, Inc. in July 2002. Altair Nanotechnologies, Inc. was founded in 1973 and is headquartered in Reno, Nevada.

THRESHOLD PHARMACEUTICALS (NASDAQ:THLD) - Threshold Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Its product line includes TH-302, a product candidate in Phase I and Phase I/II for the potential treatment of patients with cancer; and 2DG, a product candidate for the potential treatment of patients with cancer and has been evaluated in a Phase I clinical trial alone and in combination with docetaxel as a combination therapy. The company was founded in 2001 and is headquartered in Redwood City, California.

ARCELORMITTAL-NY REGISTERED (NYSE:MT) - ArcelorMittal, together with its subsidiaries, engages in the production and marketing of steel worldwide. The company offers semi-finished flat products, such as slabs; finished flat products, including plates, hot and cold rolled coils and sheets, hot dipped and electro-galvanized coils and sheets, and tinplate and color coated coils and sheets; semi-finished long products comprising blooms and billets; finished long products, such as bars, wire-rods, structural sections, rails, and wire products; seamless and welded pipes and tubes; and stainless steel products. Its products are sold primarily to customers in the distribution and processing, automotive, pipe and tubes, construction, packaging, general industry, household equipment, and appliances industries. The company, formerly known as Mittal Steel Company N.V., was founded in 1989 and is headquartered in Luxembourg.

PERMA-FIX ENVIRONMENTAL SVCS (NASDAQ:PESI) - Perma-Fix Environmental Services, Inc., through its subsidiaries, operates as an environmental and technology know-how company in the United States. It operates through three segments: Nuclear Waste Management Services (Nuclear Segment), Consulting Engineering Services (Engineering Segment), and Industrial Waste Management Services (Industrial Segment). The Nuclear Segment provides nuclear waste management services, such as treatment, storage, processing, and disposal of low-level radioactive and hazardous waste; on and off-site waste remediation and processing; nuclear, low-level radioactive, and mixed waste treatment, as well as processing and disposal; and research and development of ways to process low-level radioactive and mixed waste. The Engineering Segment offers consulting engineering services, which include consulting services regarding air, water, and hazardous waste permitting; air, soil, and water sampling; compliance reporting, emission reduction strategies, compliance auditing, and various compliance and training activities, as well as provides engineering and compliance support services. The Industrial Segment provides industrial waste management services, including treatment, storage, processing, and disposal of hazardous and non-hazardous waste; wastewater management services, including the collection, treatment, processing and disposal of hazardous and non-hazardous wastewater; and treatment, processing, recycling, and sale of used oil and other off-specification petroleum-based products. It services research institutions, commercial companies, public utilities, and governmental agencies, including the Department of Energy and Department of Defense. The company offers its services directly to customers or via intermediaries. Perma-Fix Environmental Services, Inc. was founded in 1990 and is based in Atlanta, Georgia.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641